Literature DB >> 16435103

Interleukin-10-1082 promoter polymorphism in association with cytokine production and sepsis susceptibility.

Spaska A Stanilova1, Lyuba D Miteva2, Zhivko T Karakolev3, Chavdar S Stefanov4.   

Abstract

OBJECTIVE: To investigate the -1082 (A/G) polymorphism in the promoter of the IL-10 gene in terms of IL-10 production from stimulated peripheral blood mononuclear cells (PBMC) and to evaluate the relationship of this polymorphism with susceptibility to severe sepsis and the outcome of the disease.
DESIGN: Case-control study.
SETTING: Research laboratory of Molecular Biology and Immunology and University Hospital ICU, Faculty of Medicine, Trakia University. PATIENTS: A total of 53 healthy volunteers and 33 patients in ICU meeting the criteria for severe sepsis were included. MEASUREMENTS AND
RESULTS: The amplification refractory mutation system PCR was used for IL-10-1082 polymorphism detection. Isolated PBMC were stimulated with either C3-binding glycoprotein (C3bgp), lipopolysaccharide (LPS), phytohemagglutinin (PHA),or pokeweed mitogen (PWM). IL-10 production was measured in culture supernatants. The AA genotype was associated with lower IL-10 production in LPS-, PHA- or PWM-stimulated healthy PBMC. Patients with severe sepsis had significant elevation of A allele, compared with healthy controls (74.2% vs 52.8%; p=0.0062). Carriage of at least one copy of IL-10-1082 G allele in sepsis patients and in healthy controls resulted in a statistically significant increase in IL-10 production from stimulated PBMC. Surviving sepsis patients had a significant decrease of IL-10-1082 allele G frequency, compared with controls (17% vs 47.2%; p=0.012). An association between increased IL-10 production and poor outcome from sepsis was observed.
CONCLUSION: The A allele of the -1082 polymorphism in the interleukin-10 gene promoter is associated with sepsis susceptibility, whereas G allele is associated with higher stimulated interleukin-10 production and increased mortality in severe sepsis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16435103     DOI: 10.1007/s00134-005-0022-4

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


  31 in total

1.  C3 binding glycoprotein from Cuscuta europea induced different cytokine profiles from human PBMC compared to other plant and bacterial immunomodulators.

Authors:  Spaska A Stanilova; Zlatka G Dobreva; Emil S Slavov; Lyuba D Miteva
Journal:  Int Immunopharmacol       Date:  2005-04       Impact factor: 4.932

2.  Recipient tumor necrosis factor-alpha and interleukin-10 gene polymorphisms associate with early mortality and acute graft-versus-host disease severity in HLA-matched sibling bone marrow transplants.

Authors:  J Cavet; P G Middleton; M Segall; H Noreen; S M Davies; A M Dickinson
Journal:  Blood       Date:  1999-12-01       Impact factor: 22.113

3.  Interleukin-10 impairs host defense in murine pneumococcal pneumonia.

Authors:  T van der Poll; A Marchant; C V Keogh; M Goldman; S F Lowry
Journal:  J Infect Dis       Date:  1996-11       Impact factor: 5.226

4.  Polymorphic haplotypes of the interleukin-10 5' flanking region determine variable interleukin-10 transcription and are associated with particular phenotypes of juvenile rheumatoid arthritis.

Authors:  E Crawley; R Kay; J Sillibourne; P Patel; I Hutchinson; P Woo
Journal:  Arthritis Rheum       Date:  1999-06

5.  Microsatellite alleles and single nucleotide polymorphisms (SNP) combine to form four major haplotype families at the human interleukin-10 (IL-10) locus.

Authors:  J Eskdale; V Keijsers; T Huizinga; G Gallagher
Journal:  Genes Immun       Date:  1999-11       Impact factor: 2.676

Review 6.  Cytokine and cytokine receptor polymorphisms in infectious disease.

Authors:  S J van Deventer
Journal:  Intensive Care Med       Date:  2000       Impact factor: 17.440

7.  T cell-derived IL-10 antagonizes macrophage function in mycobacterial infection.

Authors:  P J Murray; L Wang; C Onufryk; R I Tepper; R A Young
Journal:  J Immunol       Date:  1997-01-01       Impact factor: 5.422

8.  Early interleukin-10 treatment improves survival and enhances immune function only in males after hemorrhage and subsequent sepsis.

Authors:  Volker Kahlke; Christoph Dohm; Torge Mees; Kerstin Brötzmann; Stefan Schreiber; Jörg Schröder
Journal:  Shock       Date:  2002-07       Impact factor: 3.454

9.  Association of IL-10 polymorphism with severity of illness in community acquired pneumonia.

Authors:  P M Gallagher; G Lowe; T Fitzgerald; A Bella; C M Greene; N G McElvaney; S J O'Neill
Journal:  Thorax       Date:  2003-02       Impact factor: 9.139

10.  Interleukin-10 controls the onset of irreversible septic shock.

Authors:  Samir Q Latifi; Mary Ann O'Riordan; Alan D Levine
Journal:  Infect Immun       Date:  2002-08       Impact factor: 3.441

View more
  29 in total

Review 1.  Human genetic susceptibility to Candida infections.

Authors:  Theo S Plantinga; Melissa D Johnson; William K Scott; Leo A B Joosten; Jos W M van der Meer; John R Perfect; Bart Jan Kullberg; Mihai G Netea
Journal:  Med Mycol       Date:  2012-06-04       Impact factor: 4.076

2.  Cytokine gene polymorphisms and the outcome of invasive candidiasis: a prospective cohort study.

Authors:  Melissa D Johnson; Theo S Plantinga; Esther van de Vosse; Digna R Velez Edwards; P Brian Smith; Barbara D Alexander; John C Yang; Dennis Kremer; Gregory M Laird; Marije Oosting; Leo A B Joosten; Jos W M van der Meer; Jaap T van Dissel; Thomas J Walsh; John R Perfect; Bart-Jan Kullberg; William K Scott; Mihai G Netea
Journal:  Clin Infect Dis       Date:  2011-12-05       Impact factor: 9.079

3.  Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2.

Authors:  Richard A Morgan; James C Yang; Mio Kitano; Mark E Dudley; Carolyn M Laurencot; Steven A Rosenberg
Journal:  Mol Ther       Date:  2010-02-23       Impact factor: 11.454

Review 4.  Year in review in Intensive Care Medicine, 2006. I. Experimental studies. Clinical studies: brain injury, renal failure and endocrinology.

Authors:  Peter Andrews; Elie Azoulay; Massimo Antonelli; Laurent Brochard; Christian Brun-Buisson; Daniel De Backer; Geoffrey Dobb; Jean-Yves Fagon; Herwig Gerlach; Johan Groeneveld; Duncan Macrae; Jordi Mancebo; Philipp Metnitz; Stefano Nava; Jerôme Pugin; Michael Pinsky; Peter Radermacher; Christian Richard
Journal:  Intensive Care Med       Date:  2006-12-19       Impact factor: 17.440

5.  Combined effect of pro- and anti-inflammatory cytokine gene polymorphisms on susceptibility to liver cirrhosis in Tunisian HCV-infected patients.

Authors:  Nadia Bouzgarrou; Elham Hassen; Olfa Bahri; Sallouha Gabbouj; Nabil Ben Mami; Henda Triki; Lotfi Chouchane
Journal:  Hepatol Int       Date:  2011-02-08       Impact factor: 6.047

6.  Functional relevance of IL-10 promoter polymorphisms for sepsis development.

Authors:  Spaska A Stanilova
Journal:  Crit Care       Date:  2010-02-15       Impact factor: 9.097

Review 7.  Quantitative analysis of the association between interleukin-10 1082A/G polymorphism and susceptibility to sepsis.

Authors:  Lin Ouyang; You-Di Lv; Can Hou; Guo-Bao Wu; Zhi-Hui He
Journal:  Mol Biol Rep       Date:  2013-05-29       Impact factor: 2.316

Review 8.  Role of cytokines as a double-edged sword in sepsis.

Authors:  Hina Chaudhry; Juhua Zhou; Yin Zhong; Mir Mustafa Ali; Franklin McGuire; Prakash S Nagarkatti; Mitzi Nagarkatti
Journal:  In Vivo       Date:  2013 Nov-Dec       Impact factor: 2.155

9.  Serial cytokine levels in patients with severe sepsis.

Authors:  Huang-Pin Wu; Chian-Kuang Chen; Kong Chung; Jo-Chi Tseng; Chung-Ching Hua; Yu-Chih Liu; Duen-Yau Chuang; Chung-Han Yang
Journal:  Inflamm Res       Date:  2009-03-05       Impact factor: 4.575

10.  Clinical relevance of the interleukin 10 promoter polymorphisms in Chinese Han patients with major trauma: genetic association studies.

Authors:  Ling Zeng; Wei Gu; Kehong Chen; Dongpo Jiang; Lianyang Zhang; Dingyuan Du; Ping Hu; Qing Liu; Suna Huang; Jianxin Jiang
Journal:  Crit Care       Date:  2009-11-26       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.